Search Results for: Immupharma

ImmuPharma PLC (LON:IMM, the specialist drug discovery and development company, has announced that it has entered into agreements with two specialist US healthcare investors for a total investment of up

ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced that with immediate effect, its registered office address has been changed to: One Bartholomew Close, London, EC1A 7BL.

ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, today announced that the Company’s Annual General Meeting confirmed for Thursday, 18 June 2020 @ 10.30am, will now be held at: 52

ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, today provided a progress update on activities around Covid-19. On 30 March 2020, ImmuPharma announced that it had expanded its

ImmuPharma plc (LON:IMM), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2019. Key Highlights (including post Period review)

ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced subscriptions to raise £1.5 million through the issue of 15,000,000 new ordinary share of 10 pence each

ImmuPharma PLC (LON:IMM), a specialist drug discovery and development company, today noted that further to its announcement on 17 February 2020,  Incanthera plc, a specialist oncology company, has today been

ImmuPharma PLC (LON:IMM), a specialist drug discovery and development company, has today announced an update on activities with Avion Pharmaceuticals LLC following the successful licence and development agreement signed with

ImmuPharma (LON: IMM) is a United Kingdom domiciled clinical stage therapeutics and Biotechnology company that has interests in the Research and development of novel therapeutics compounds as well as manufacturing